Back to search results

Observational Study of iPSCs for Diabetic Retinopathy

This study is looking at how human inducible pluripotent stem cells (iPSCs) might help repair damaged blood vessels in people with diabetic retinopathy (eye damage from diabetes). Researchers will create iPSCs from your blood cells. These iPSCs will then be used to make other types of cells, called mesoderm cells and CD34+CD45+ cells. The study aims to see if these cells can help grow new blood vessels in areas where they are damaged. You can join if you are 21 to 98 years old and have diabetes or are a healthy older adult. You must also be willing to have an eye exam and a small skin biopsy. The main goals are to successfully create iPSCs from your blood and then turn them into mesoderm and CD34+ cells. The current status of this study is unclear.

Study design
This is an observational study with a planned enrollment of 20 participants. It is not specified if it is randomized or blinded.
What's involved
You will need to provide a blood sample for iPSC generation and undergo an eye exam and a skin punch biopsy. The process of generating iPSCs and differentiating them into other cell types can take from 4 months to 4 years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for the differentiation of iPSCs into CD34+ cells and mesoderm, which is measured from 4 months to 4 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03403699

Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy

Recruiting
Not specifiedAges 21–98Observational
University of Alabama at Birmingham
~20 participants
Updated 2026-01-22 on ClinicalTrials.gov
What's tested:Generation of inducible pluripotent stem cells

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Generating iPSCs from peripheral blood
Measured over From blood draw to 4 months
+1 more outcome measured

Conditions

Diabetes Complications
Diabetic Retinopathy

Explore related trials

Diabetes MellitusDiabetic Retinopathy

Where it's being run

1 sites across 1 states
Alabama1

Study leadership

  • Maria B Grant, MD · PRINCIPAL_INVESTIGATOR · 1954

Who to contact

Jennifer Moorer
[email protected]
205 325 8674
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) the subject must either carry the diagnosis of diabetes or be a healthy aged control and b) the patient be willing and have the ability to cooperate with the eye exam and skin punch biopsy protocol.

What this trial measures

  • Generating iPSCs from peripheral bloodFrom blood draw to 4 months

    Blood will be collected from the patient and cells will be isolated and shipped to ALSTEM for generation of iPSCs

  • Differentiate iPSCs into CD34+ cells and mesoderm4 months to 4 years

    Specific cell culture conditions will be used to differentiate the cells into these two distinct populations